Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-12
2007-06-12
Ungar, Susan (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230
Reexamination Certificate
active
09164862
ABSTRACT:
This invention provides methods for detecting cancers and for evaluating the prognosis of cancer patients. In particular, the methods of this invention utilize YKL-40 as a marker for the presence or absence of a cancer and for the prognosis (e.g. likelihood of recurrence) of a cancer. Elevated levels of YKL-40 are indicative of the presence of a cancer in undiagnosed subjects and indicate likely recurrence of the cancer in subjects diagnosed as having a cancer.
REFERENCES:
patent: 4628027 (1986-12-01), Gay
patent: 4828981 (1989-05-01), Maggio
patent: 5726061 (1998-03-01), Robbins et al.
patent: 5773259 (1998-06-01), Kirkpatrick
patent: 0 805 206 (1997-11-01), None
patent: 63023898 (1986-07-01), None
patent: WO 93/22429 (1993-11-01), None
patent: WO 95/01995 (1995-01-01), None
patent: WO 95 01995 (1995-01-01), None
patent: WO9501995 (1995-01-01), None
patent: WO 98 06859 (1998-02-01), None
Johansen et al. European J. Cancer. vol. 31A, 1437-1442, 1995.
Harlow et al. Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory, pp. 148-212, 1988.
Tockman et al (Cancer Research, 1992, 52:2711s-2718s).
Nordenbaek et al (J. Infectious Diseases, 1999, 180:1722-1726).
Ostergaard et al (Abstracts of the Interscience Conference on Antimicrobial Agents and Chemothrapy, 2000, 40:45).
Kronberg et al (Abstracts on the Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001, 41:460).
Price et al (WO20000019206).
Kronberg et al (Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001, 41:460).
Guinan et al (Urology, 1975, 6:693-696).
Veronesi et al (Lancet, 1997, 349:1864-1867).
Moertel et al 9J. Natl Can Inst., 1975, 54:69-71).
Joasson et al (Nouvelle Press Medicale, 1979, 8:3665).
Osband and Ross (Immunology Today, 1990, 11:193-195).
EMHUM2 Database Accession No. HSU58514 (Jul. 26, 1996) from Grossman et al., “Cloning of a Novel Lymphoid Restricted Human Chitinase and Localization to 1p13.3 (unpublished)”—abstract.
EMHUM2 Database Accession No. HSU58515 (Jul. 26, 1996) from Grossman et al., “Cloning of a Novel Lymphoid Restricted Human Chitinase and Localization to 1p13.3 (unpublished)”—abstract.
EMHUM2 Database Accession No. HSU49835 (Jul. 27, 1996)—abstract.
TRHUM Database Accession Nos. Q15749, Q15782 and Q15783 (Nov. 1, 1996)—abstract.
Hu, B. et al.J. Biol. Chem., 271(32):19415-19420.
Renkema, G. et al. (1995)J. Biol. Chem., 270(5):2198-2202.
European Search Report (1999) for European Patent Application No. EP 0 823 478 A3.
Johansen, JS:, et al “Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer”European Journal of Cancervol. 31a, No. 9, 1995, pp. 1437-1442.
Kirkpatrick, RB:, et al., “Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages”Experimental Cell Research, vol. 237, No. 1, Nov. 25, 1997, pp. 46-54.
Renkema:, et al., “Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glcosal hydrolases secreted by human macrophages,”European Journal of Biochemistry, DE, BERLIN, vol. 251, No. 251, Jan. 1998 pp. 504-509-509.
Baslund, B.: (1) et al., “YKL-40 in the circulation and temporal artery in patients with giant cell arteritis and polymyalgia rheuamatica.”Arthritis&Rheumatism, (Sep. 1998) vol. 41, No. 9 Suppl., pp. S118.
Boot, Rolf G., et al.: “Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages”Arterioscler., Thromb., Vasc. Biol. (Mar. 1999), 19(3), 687-694.
Nordenbaek C, et al: “YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization.”Journal of Infectious Diseases(Nov. 1999) 180 (5) 1722-6.
Volck B., et al.: “YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils”Proceedings of the Association of American Physicians, vol. 110, No. 4, Jul. 1998, pp. 351-360.
Been et al. (1986)Cell47: 207-216.
Campbell (1991) Monoclonal Antibodies and Immunosensor Technology. In Laboratory Techniques iBiochemistry and Molecular Biology, 23: 1-114, Elsevier, N.Y.
Gillies et al. (1989)Bio/Technology, 7: 799-805.
Gorman et al. (1982)Proc. Natl. Acad. Sci. USA, 79: 6777-6781.
Hakala et al. (1993)J. Biol. Chem., 268 (34): 25803-25810.
Horslev-Petersen et al. (1986)Arthritis and Rheumatism, 29(5) 592-599.
Horslev-Petersen et al. (1988)Clinical&Experimental Rheumatology, 6: 129-134.
Isselbacher et al. (1976)Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y., pp. 1865-1867, 1870-1879, 1894-1896.
Johansen et al. (1992)J. Bone and Mineral Res., 7(5): 501-512.
Johansen et al. (1992) Plasma YKL-40 concentrations in patients with rheumatoid arthritis, Abstract for Scientific Conference published on or after Jul. 12, 1992 in Davos, Switzerland.
Johansen et al. (1993)Br. J. Rheumatology, 32(11): 949-955.
Krieq et al. (1984)Nucleic Acids Res., 12 (18): 7057-7071.
MacNaul et al. (1990) J. Biol. Chem., 265 (28): 17238-17245.
Maurer et al. (1980)Meth. Enzymol., 70: 49-70.
Norton et al. (1985)Mol. and Cellular Biol., 5(2): 281-290.
Nyirkos et al. (1990)Biochem, J., 268: 265-268.
Raz et al. (1993)Proc. Nat. Acad. Sci., 90(10): 4523-4527.
Rejman et al. (1988)Biochem. Biophys.Res. Comm., 150 (1) 329-334.
Rhode et al. (1979)Eur. J. Clin. Investigation, 9: 451-459.
Salacinski et al. (1981)Anal. Biochem., 117: 136-146.
Saxne et al.,Annal. Rheumatic Dis., 45: 491-497.
Thomas (1988)Tabers Cyclopedic Medical Dictionary, F.A. Davis, Philadelphia. pp. 372-373.
Ulmer et al. (1992)Science, 259: 1745-1749.
Ward et al. (1989)Nature, 341: 544-546.
Johansen et al. (1995) “Serun YKL-40: A New Potential Marker of Prognosis and Location of Metastases of Patients with Recurrent Breast Cancer”, EP J. Cancer 3a(9): 1437-1442.
Kirkpatrick et al. (1997) “Induction and Expression of Human Cartilage Glycoprotein 39 in Rheumatoid Inflammatory and Peripheral Blood Monocyte-Derived Macrophages”, Experimental Cell Research 237(1): 46-54.
Renkema et al. (1998) “Chitotriosidase, a Chitinase, and the 39-kDa Human Cartilage Glycoprotein, a Chitin-Binding Lectin, are Homologues of Family 18 Glycosal Hydolases Secreted by Human Macrophages”, EP J. Biochem. DE, Berlin. 251(251): 504-509.
Baslund et al. (1998) “YKL-40 in the Circulation and Temporal Artery in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica”, 41(9):S118.
Boot et al. (1999) “Strong Induction of Members of the Chitinase Family of Proteins in Arherosclerosis: Chitotrisidase and Human Cartilage gp-39 Expresses in Lesion Macrophages”, 19(3) 687-694.
Nordenbaek et al. (1999) “YKL-40, A Matrix Protein of Specific Granules in Neutrophils, is Elevated in Serum of Proteins with Community-Aquired Pneumonia Requiring Hospitalization” J. of Infec. Dis. 180(5): 1722-1726.
Volck et al. (1998) “YKL-40, A Mammalian Member of the Chitinase Family, is a Matrix Protein of Specific Granules in Human Neutrophils”, Proceedings of the Association of American Physicians, 110(4):351-360.
Brasso K, Johansen JS, Christensen IJ, Teisner B, Price PA, Iversen P. High serum levels of PINP, bone alkaline phosphatase and YKL-40 in patients with advanced prostate carcinoma are associated with short survival. Meeting Proceedings of American Society for Clinical Oncology ASCO 2003; 22:abstract 1525.
Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Brit J Cancer 79:1494-1499, 1999.
Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma ise related to short survival. Cancer 95
Johansen Julia S.
Price Paul A.
Beyer & Weaver, LLP
Hunter Tom
The Regents of the University of California
Ungar Susan
LandOfFree
YKL-40 as a marker and prognostic indicator for cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with YKL-40 as a marker and prognostic indicator for cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and YKL-40 as a marker and prognostic indicator for cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3830049